Clinical Trial Update: Safety and Pharmacokinetics of ODM-209 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on safety and pharmacokinetics of ODM-209 for metastatic prostate cancer and advanced/metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ODM-209

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Prostate Cancer Metastatic, Advanced Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED